Get the Stockscreener App
0.45
1.98%
-0.0091
Sangamo Therapeutics Inc stock is traded at $0.45, with a volume of 4.42M.
It is down -1.98% in the last 24 hours and down -4.26% over the past month.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
See More
Previous Close:
$0.4591
Open:
$0.4625
24h Volume:
4.42M
Relative Volume:
0.70
Market Cap:
$151.42M
Revenue:
$52.29M
Net Income/Loss:
$-134.84M
P/E Ratio:
-0.60
EPS:
-0.75
Net Cash Flow:
$-117.11M
1W Performance:
-9.26%
1M Performance:
-4.26%
6M Performance:
-10.54%
1Y Performance:
-76.44%
1-Day Range:
$0.4496
$0.4682
1-Week Range:
$0.4496
$0.5127
52-Week Range:
$0.3846
$2.84
Sangamo Therapeutics Inc Stock (SGMO) Company Profile
Name
Sangamo Therapeutics Inc
Sector
Industry
Phone
(510) 970-6000
Address
501 CANAL BLVD., RICHMOND, CA
Compare SGMO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SGMO
Sangamo Therapeutics Inc
|
0.45 | 154.48M | 52.29M | -134.84M | -117.11M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-07-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-13-24 | Upgrade | Truist | Hold → Buy |
| Dec-10-24 | Reiterated | H.C. Wainwright | Buy |
| Nov-03-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Apr-28-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Feb-27-23 | Upgrade | Wedbush | Neutral → Outperform |
| Jan-06-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-13-22 | Resumed | Wedbush | Neutral |
| May-04-21 | Initiated | RBC Capital Mkts | Outperform |
| Jan-07-21 | Resumed | Guggenheim | Neutral |
| Jan-06-21 | Initiated | Stifel | Hold |
| Dec-16-20 | Resumed | H.C. Wainwright | Buy |
| Sep-08-20 | Initiated | BofA Securities | Buy |
| Jul-07-20 | Initiated | SunTrust | Buy |
| Aug-26-19 | Initiated | H.C. Wainwright | Buy |
| Nov-14-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-09-18 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-10-18 | Initiated | Guggenheim | Buy |
| Jun-20-18 | Initiated | BofA/Merrill | Buy |
| Nov-15-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-22-17 | Resumed | Jefferies | Buy |
| Nov-01-16 | Downgrade | Wedbush | Outperform → Neutral |
| Oct-19-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Dec-04-15 | Initiated | Wells Fargo | Outperform |
| Oct-23-15 | Resumed | Jefferies | Buy |
| May-03-13 | Initiated | BioLogic Equity Research | Sell |
| Feb-23-11 | Reiterated | JMP Securities | Mkt Outperform |
| Jul-29-10 | Reiterated | Wedbush | Outperform |
| Oct-19-09 | Initiated | Brean Murray | Sell |
| Oct-07-09 | Reiterated | Leerink Swann | Outperform |
| Aug-25-09 | Reiterated | JMP Securities | Mkt Outperform |
View All
Sangamo Therapeutics Inc Stock (SGMO) Latest News
How the Narrative Surrounding Sangamo Therapeutics Is Shifting After New Regulatory and Valuation Signals - Yahoo Finance
Inflation Data: Is Sangamo Therapeutics Inc stock positioned well for digital economy2025 Breakouts & Breakdowns & Long Hold Capital Preservation Tips - moha.gov.vn
Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy - Zenopa
Is Sangamo Therapeutics Stock Built to Withstand a Pullback? - Trefis
Sangamo rises as FDA grants Fast Track status to neuropathic pain asset - MSN
Why analysts recommend Sangamo Therapeutics Inc. (GBY) stockQuarterly Earnings Summary & Precise Buy Zone Identification - Newser
Will Sangamo Therapeutics Inc. (GBY) stock maintain strong growthBreakout Watch & Real-Time Buy Signal Alerts - Newser
Sangamo Therapeutics Inc at Evercore ISI HealthCONx Conference (Virtual) Transcript - GuruFocus
Can Sangamo Therapeutics Inc. (GBY) stock attract analyst upgrades2025 Bull vs Bear & AI Powered Buy and Sell Recommendations - Newser
Can Sangamo Therapeutics Inc. (GBY) stock reach $200 price targetPortfolio Gains Report & Low Risk High Win Rate Stock Picks - Newser
How reliable is Sangamo Therapeutics Inc. (GBY) stock dividend growth2025 Momentum Check & Expert Curated Trade Setup Alerts - Newser
How Sangamo Therapeutics Inc. (GBY) stock reacts to fiscal policiesQuarterly Trade Review & Capital Efficient Trading Techniques - Newser
SGMO SEC FilingsSangamo Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
FDA grants fast track designation for Sangamo’s pain treatment By Investing.com - Investing.com Canada
How Sangamo Therapeutics Inc. (GBY) stock performs in volatility spikesMarket Growth Report & Expert Approved Momentum Trade Ideas - Newser
Sangamo Therapeutics (SGMO) Stock: Gains FDA Fast Track for ST-503 in SFN Pain Treatment - parameter.io
Lacklustre Performance Is Driving Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 29% Price Drop - 富途牛牛
Sangamo Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy - marketscreener.com
Sangamo Therapeutics (SGMO) Surges on FDA Fast Track Designation for ST-503 - GuruFocus
Sangamo (SGMO) Gains FDA Fast Track for Chronic Pain Treatment - GuruFocus
Sangamo Therapeutics secures FDA fast track for ST-503 - Traders Union
Sangamo Therapeutics receives U.S. FDA fast track designation for ST-503 - marketscreener.com
Sangamo Therapeutics (Nasdaq: SGMO) gets FDA Fast Track for ST-503 in small fiber neuropathy - Stock Titan
Sangamo Therapeutics (SGMO) Stock Analysis Report | Financials & Insights - Benzinga
Is Sangamo Therapeutics Inc. (GBY) stock a top hedge fund pick2025 Technical Patterns & High Yield Stock Recommendations - Newser
Earnings Report: Is Sangamo Therapeutics Inc. stock attractive for retirement portfolios2025 Top Gainers & Capital Efficient Trading Techniques - BỘ NỘI VỤ
Sangamo Therapeutics Q3 2025 Earnings Preview - MSN
Sangamo Therapeutics, Inc. (GBY.F) Stock Price, News, Quote & History - Yahoo! Finance Canada
How Recent Developments Are Rewriting the Story for Sangamo Therapeutics - Yahoo Finance
With Sangamo Therapeutics Stock Sliding, Have You Assessed The Risk? - Trefis
[Form 4] SANGAMO THERAPEUTICS, INC Insider Trading Activity - Stock Titan
SGMO Form 4: CEO RSU vesting and 2.05M shares owned - Stock Titan
SGMO insider reports RSU tax withholding, 696,718 shares owned - Stock Titan
What drives Sangamo Therapeutics Inc. (GBY) stock priceCandlestick Trading Patterns & High Return Investment Ideas - earlytimes.in
Sangamo rises as FDA accepts rolling submission request for gene therapy - MSN
Revenues Working Against Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Share Price Following 33% Dive - simplywall.st
What analysts say about Sangamo Therapeutics Inc GBY stockDividend Yield Trends & The Smart Money Is Buying These Picks - earlytimes.in
Sangamo Therapeutics, Inc. (SGMO) Stock: Soars 9.95% on FDA Milestone for Gene Therapy - parameter.io
With cash running low, East Bay biotech Sangamo bets on FDA submission strategySan Francisco Business Times - The Business Journals
Sangamo Therapeutics Gets US FDA Approval to Begin Rolling BLA Submission for Fabry Gene Therapy - marketscreener.com
Sangamo Therapeutics (SGMO) Advances Fabry Disease Therapy with FDA Rolling Submission - GuruFocus
Sangamo (SGMO) Advances Gene Therapy for Fabry Disease with FDA Approval Process - GuruFocus
FDA accepts Sangamo’s rolling BLA submission for Fabry disease gene therapy - Investing.com Canada
Sangamo Therapeutics announces FDA acceptance of BLA rolling submission request - marketscreener.com
Sangamo Therapeutics Announces FDA Acceptance of Rolling Submission for Gene Therapy ST-920 for Fabry Disease Treatment - Quiver Quantitative
Sangamo stock climbs after FDA accepts BLA rolling submission request By Investing.com - Investing.com Canada
Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease - The Manila Times
Sangamo (Nasdaq: SGMO) rolling ST-920 Fabry BLA accepted by FDA for accelerated review - Stock Titan
Will Sangamo Therapeutics Inc. (GBY) stock rise with strong economyWeekly Trend Report & Verified Technical Trade Signals - newser.com
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Will Sangamo Therapeutics Inc. (GBY) stock gain from green policiesQuarterly Investment Review & Safe Entry Trade Reports - newser.com
Sangamo Therapeutics Inc Stock (SGMO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):